Search Menu
Photonics Media Photonics Buyers' Guide Photonics EDU Photonics Spectra BioPhotonics EuroPhotonics Industrial Photonics Photonics Showcase Photonics ProdSpec Photonics Handbook
More News
Email Facebook Twitter Google+ LinkedIn Comments

Invitrogen Corp.

May 2006
Invitrogen Corp. of Carlsbad, Calif., has entered into an agreement with the National Institutes of Health Chemical Genomics Center in Bethesda, Md., to identify small molecules that modulate key signaling pathways associated with disease pathophysiology. The center will use the company’s CellSensor cell lines and GeneBLAzer β-lactamase reporter gene technology to identify compounds that modulate disease signaling pathways. All of the data will be deposited in PubChem, an NIH database that links chemical structures to biological activities uncovered through screening campaigns. The research community will have access to the database.

BiophotonicsBusinessRapidScanSensors & Detectors

Terms & Conditions Privacy Policy About Us Contact Us
back to top
Facebook Twitter Instagram LinkedIn YouTube RSS
©2019 Photonics Media, 100 West St., Pittsfield, MA, 01201 USA,

Photonics Media, Laurin Publishing
x Subscribe to BioPhotonics magazine - FREE!
We use cookies to improve user experience and analyze our website traffic as stated in our Privacy Policy. By using this website, you agree to the use of cookies unless you have disabled them.